Literature DB >> 21547501

How tumors might withstand γδ T-cell attack.

Aude-Hélène Capietto1, Ludovic Martinet, Jean-Jacques Fournié.   

Abstract

Several clinical trials are currently assessing the therapeutic activity of human TCRVγ9Vδ2(+) lymphocytes in cancer. Growing tumors usually follow a triphasic "Elimination, Equilibrium, Escape" evolution in patients. Thus, at diagnostic, most tumors have already developed some means to escape to immune protection. We review here the conventional immunoescape mechanisms which might also protect against cytolytic TCRVγ9Vδ2(+) lymphocytes activated by phosphoantigens. Neutralization of these deleterious processes might prove highly valuable to improve the efficacy of ongoing γδ cell-based cancer immunotherapies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21547501     DOI： 10.1007/s00018-011-0705-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  130 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

3.  Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

Authors:  A H Enk; H Jonuleit; J Saloga; J Knop
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

4.  Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.

Authors:  A Choudhary; F Davodeau; A Moreau; M A Peyrat; M Bonneville; F Jotereau
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

5.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

6.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

Authors:  Xuefang Cao; Sheng F Cai; Todd A Fehniger; Jiling Song; Lynne I Collins; David R Piwnica-Worms; Timothy J Ley
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

7.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

8.  Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells.

Authors:  R M Dwyer; S M Potter-Beirne; K A Harrington; A J Lowery; E Hennessy; J M Murphy; F P Barry; T O'Brien; M J Kerin
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Primary activation of V gamma 9-expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Th1-type CD4 T cell help and inhibition by IL-10.

Authors:  K Pechhold; D Wesch; S Schondelmaier; D Kabelitz
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

10.  Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck.

Authors:  Thomas K Hoffmann; Jan Müller-Berghaus; Robert L Ferris; Jonas T Johnson; Walter J Storkus; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531
View more
  10 in total

Review 1.  Dynamics of the interaction of γδ T cells with their neighbors in vivo.

Authors:  Immo Prinz
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

2.  Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Authors:  Cédric Rossi; Pauline Gravelle; Emilie Decaup; Julie Bordenave; Mary Poupot; Marie Tosolini; Don-Marc Franchini; Camille Laurent; Renaud Morin; Jean-Michel Lagarde; Loïc Ysebaert; Laetitia Ligat; Christine Jean; Ariel Savina; Christian Klein; Alba Matas Céspedes; Patricia Perez-Galan; Jean-Jacques Fournié; Christine Bezombes
Journal:  Oncoimmunology       Date:  2018-12-17       Impact factor: 8.110

Review 3.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 4.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

5.  Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.

Authors:  Jingwei Lu; Manjusri Das; Suman Kanji; Reeva Aggarwal; Matthew Joseph; Alo Ray; Charles L Shapiro; Vincent J Pompili; Hiranmoy Das
Journal:  Biochim Biophys Acta       Date:  2014-04-13

6.  A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.

Authors:  Aurélie Thedrez; Vincent Lavoué; Benoit Dessarthe; Pascale Daniel; Sébastien Henno; Isabelle Jaffre; Jean Levêque; Véronique Catros; Florian Cabillic
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

Review 7.  Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.

Authors:  Heleen H Van Acker; Sébastien Anguille; Viggo F Van Tendeloo; Eva Lion
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

8.  Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.

Authors:  Wen Li; Akico Okuda; Hideyuki Yamamoto; Kyosuke Yamanishi; Nobuyuki Terada; Hiromichi Yamanishi; Yoshimasa Tanaka; Haruki Okamura
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

Authors:  Heleen H Van Acker; Sébastien Anguille; Yannick Willemen; Johan M Van den Bergh; Zwi N Berneman; Eva Lion; Evelien L Smits; Viggo F Van Tendeloo
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

Review 10.  γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.

Authors:  Elena Lo Presti; Gabriele Pizzolato; Anna Maria Corsale; Nadia Caccamo; Guido Sireci; Francesco Dieli; Serena Meraviglia
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.